Comprehensive study of GLP‐1 effects suggests neuropsychiatric benefits

A study evaluating the effects of glucagon‐like peptide‐1 (GLP‐1) receptor agonists on 175 health outcomes found an association with lower risk of substance use, psychotic, and neurocognitive disorders in patients diagnosed with diabetes. Conversely, use of GLP‐1 drugs was associated with higher risk of gastrointestinal disorders.

Publication Details

Journal: The Brown University Psychopharmacology Update
Published: 2025-03-27
DOI: https://doi.org/10.1002/pu.31301
Primary Topic: Diet and metabolism studies
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Comprehensive study of GLP‐1 effects suggests neuropsychiatric benefits

Mar 27, 2025

The Brown University Psychopharmacology Update

Diet and metabolism studies

article

Comprehensive study of GLP‐1 effects suggests neuropsychiatric benefits

March 27, 2025article en

Abstract

The Brown University Psychopharmacology UpdateVol. 36(5)

Openalex Percentile: Top 92%

Diet and metabolism studies

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Comprehensive study of GLP‐1 effects suggests neuropsychiatric benefits · The Brown University Psychopharmacology Update (2025) | TGRS Research Map | TGRS